CFTR modulates lung secretory cell proliferation and differentiation

Area of Science:

• Developmental Biology
• Gene Therapy
• Respiratory Medicine

Background:

• Cystic Fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
• The CFTR protein is crucial for regulating ion transport across epithelial surfaces.
• Developing effective gene therapies for CF remains a significant challenge.

Purpose of the Study:

• To investigate the potential of in utero gene therapy to permanently correct CFTR deficiency.
• To evaluate the long-term effects of gene transfer targeting somatic stem cells in developing organs.
• To assess the impact of CFTR gene delivery on lung and intestinal epithelial development.

Main Methods:

• Adenovirus-mediated delivery of the cftr gene into developing mouse embryos.
• Targeting of somatic stem cells in the lung and intestinal tissues.
• Morphometric and biochemical analyses to evaluate secretory cell proliferation and differentiation.
• Survival statistics analysis of treated and untreated progeny.

Main Results:

• Permanent reversal of the lethal phenotype in CFTR-deficient mice following in utero gene therapy.
• Demonstrated permanent developmental changes in lung and intestinal epithelial surfaces.
• Observed increased mortality in homozygous normal pups, indicating detrimental effects of CFTR gene overexpression during development.
• Accelerated secretory cell proliferation and differentiation in the lungs of overexpressing pups.

Conclusions:

• In utero gene therapy can permanently correct CFTR deficiency in a mouse model.
• CFTR gene delivery to developing tissues has lasting effects on epithelial development.
• Precise regulation of CFTR expression is critical during development to avoid adverse outcomes.